Medical Education Library

Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults

Publish date: August 14, 2018
This supplement is sponsored by Salix Pharmaceuticals.

 

Click to read supplement.

In this supplement to Family Practice News , Christine Frissora, MD, provides an overview of the burdens that patients with IBS-D experience. Three clinical efficacy and safety studies surrounding an FDA-approved treatment are also examined.

Topics include:

  • IBS-D diagnosis and treatment challenges
  • The role of microbial imbalance and altered gut microbiota
  • A treatment option for relief of IBS-D symptoms

Click to read supplement.

XIFI.0273.USA.18

Recommended Reading

NAFLD less common, more severe in black children
MDedge Family Medicine
Children’s ‘gluten-free’ foods are no healthier than others
MDedge Family Medicine
Diverticulitis: A Primer for Primary Care Providers
MDedge Family Medicine
What’s the best secondary treatment for patients who fail initial triple therapy for H pylori?
MDedge Family Medicine
Psychological screening integration improves quality of care for children with abdominal pain
MDedge Family Medicine
Pediatric appendectomy fast track reduced LoS, narcotic use
MDedge Family Medicine
Liver cancer death rates down for Asians and Pacific Islanders
MDedge Family Medicine
Weight gain linked to progression of fibrosis in NAFLD patients
MDedge Family Medicine
Genetic composition of HCV changes with HIV coinfection
MDedge Family Medicine
Immunosuppression often triggers skin side effects
MDedge Family Medicine